Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy

Celis-Gutierrez, Javier, Blattmann, Peter, Zhai, Yunhao, Jarmuzynski, Nicolas, Ruminski, Kilian, Grégoire, Claude, Ounoughene, Youcef, Fiore, Frédéric +4 more·2019·Cell Reports
DOI 10.1016/j.celrep.2019.05.041

Cited by (155)

Items 101–155 of 155

  1. DNA damage repair profiling of esophageal squamous cell carcinoma uncovers clinically relevant molecular subtypes with distinct prognoses and therapeutic vulnerabilities
    Ning Zhao, Zicheng Zhang, Qiang Wang, Lin Li, Zichao Wei, Hongyan Chen, Meng Zhou, Zhihua Liu, Jianzhong Su · 2023 · EBioMedicine
  2. PD1 inhibits PKCθ-dependent phosphorylation of cytoskeleton-related proteins and immune synapse formation
    Daniela Chmiest, Silvia Podavini, Kalliopi Ioannidou, David Vallois, Chantal Décaillet, Montserrat Gonzalez, Manfredo Quadroni, Kevin Blackney, Rebekka Schairer, Laurence de Leval et al. · 2024 · Blood Advances
  3. Polymer-based antibody mimetics (iBodies) target human PD-L1 and function as a potent immune checkpoint blocker
    Mohammad Reza Zamani, Martin Hadzima, Kristýna Blažková, Vladimír Šubr, Tereza Ormsby, Javier Celis‐Gutierrez, Bernard MALISSEN, Libor Kostka, Tomáš Etrych, Pavel Šácha et al. · 2024 · Journal of Biological Chemistry
  4. Current Status of Immune Checkpoint Inhibitors and Treatment Responsive Biomarkers for Triple‐Negative Breast Cancer
    Xinran Wang, Lingxia Wang, Yueping Liu · 2025 · Thoracic Cancer
  5. Exploration of T cell immune responses by expression of a dominant-negative SHP1 and SHP2
    Julia Taylor, Anna M. Bulek, Isaac Gannon, Mathew P. Robson, Evangelia Kokalaki, Thomas Grothier, Callum McKenzie, Mohamed El-Kholy, Maria Stavrou, Charlotte Traynor-White et al. · 2023 · Frontiers in Immunology
  6. Efficient Immune Cell Genome Engineering with Enhanced CRISPR Editing Tools
    Waipan Chan, Rachel A. Gottschalk, Yikun Yao, Joel L. Pomerantz, Ronald N. Germain · 2021 · ImmunoHorizons
  7. Microbial Protein Binding to gC1qR Drives PLA2G1B-Induced CD4 T-Cell Anergy
    Julien Pothlichet, Annalisa Meola, Florence Bugault, Louise Jeammet, Anne G. Savitt, Berhane Ghebrehiwet, Lhousseine Touqui, Philippe Pouletty, Frédéric FIORE, Alain Sauvanet et al. · 2022 · Frontiers in Immunology
  8. Differential impact of genetic deletion of TIGIT or PD-1 on melanoma-specific T-lymphocytes
    Gwenann Cadiou, Tiffany Beauvais, Lucine Marotte, Sylvia Lambot, Cécile Deleine, Caroline Vignes, Malika Gantier, Melanie Hussong, Samuel J. Rulli, Anne Jarry et al. · 2024 · OncoImmunology
  9. SLAMF6 as a drug-targetable suppressor of T cell immunity against cancer
    Bin Li, Ming‐Chao Zhong, Cristian Camilo Galindo, Jiayu Dou, Jin Qian, Zheng-Hai Tang, Dominique Davidson, André Veillette · 2026 · Nature
  10. BTLA and PD-1 signals attenuate TCR-mediated transcriptomic changes
    Muhammad Zainul Arifin, Judith Maria Leitner, Donagh Egan, Petra Waidhofer‐Söllner, Walter Kölch, Vadim Zhernovkov, Peter Steinberger · 2024 · iScience
  11. Integrative In Silico Analysis to Identify Functional and Structural Impacts of nsSNPs on Programmed Cell Death Protein 1 (PD-1) Protein and UTRs: Potential Biomarkers for Cancer Susceptibility
    Hakeemah H. Al-nakhle, Retaj Al-Shahrani, Jawanah Al-Ahmadi, Wesal Al-Madani, Rufayda Al-Juhani · 2025 · Genes
  12. Regulation of T cell receptor (TCR) signaling by tyrosine phosphatases: Recent advances and implication for therapeutic approach in autoimmune diseases
    Chien‐Sheng Wu, Feng‐Cheng Liu, Shih‐Chang Lin, I‐Tsu Chyuan · 2025 · Journal of the Formosan Medical Association
  13. Targeting B and T lymphocyte attenuator in cancer immunotherapy
    Keywan Mortezaee · 2025 · International Journal of Biological Macromolecules
  14. The role and targeting strategies of non-coding RNAs in immunotherapy resistance in oral squamous cell carcinoma
    Zhinan Liang, Yicheng Zhao, Xin Wang, Yubao Li · 2025 · Frontiers in Cell and Developmental Biology
  15. TMED inhibition suppresses cell surface PD-1 expression and overcomes T cell dysfunction
    David W. Vredevoogd, Georgi Apriamashvili, Pierre L. Levy, Sanju Sinha, Zowi R. Huinen, Nils L. Visser, Beaunelle de Bruijn, Julia Boshuizen, Susan E. van Hal-van Veen, Maarten Alexander Ligtenberg et al. · 2024 · Journal for ImmunoTherapy of Cancer
  16. Regulation and activity of the phosphatase SHP2: SH2 domains, dephosphorylation activity, and beyond
    Catia L. Pierotti, Maja Köhn · 2026 · Biochemical Society Transactions
  17. Prognostic Signature Development on the Basis of Macrophage Phagocytosis‐Mediated Oxidative Phosphorylation in Bladder Cancer
    Genyi Qu, Yong Xu, Zhenquan Lu, Hai-bo Nie, Cheng Tang, Jian Yong Hou, Xiangyang Wen · 2022 · Oxidative Medicine and Cellular Longevity
  18. A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity
    Shuwei Liang, Eric Tran, Xin Du, Jiajun Dong, Harrison Sudholz, Hao Chen, Zihan Qu, Nicholas D. Huntington, Jeffrey J. Babon, Nadia J. Kershaw et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  19. A CARMIL2 gain-of-function mutation suffices to trigger most CD28 costimulatory functions in vivo
    Fanghui Zhang, Javier Celis‐Gutierrez, Lichen Zhang, Valentin Mellado, Léna Gelard, Sophie Panigot, Daiki Mori, Liaoxun Lu, Guillaume Voisinne, Carine Vilarnau Wolek et al. · 2025 · The Journal of Experimental Medicine
  20. Mapping the SLP76 interactome in T cells lacking each of the GRB2-family adaptors reveals molecular plasticity of the TCR signaling pathway
    Kilian Ruminski, Javier Celis‐Gutierrez, Nicolas Jarmuzynski, Emilie Maturin, Stéphane Audebert, Marie Malissen, Luc Camoin, Guillaume Voisinne, Bernard MALISSEN, Romain Roncagalli · 2023 · Frontiers in Immunology
  21. Simulating the Evolution of Signaling Signatures During CART-Cell and Tumor Cell Interactions
    Viren Shah, Justin A. Womack, Anthony Elston Zamora, Scott S. Terhune, Ranjan K. Dash · 2023 · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC)
  22. Platforms for studying cell–cell recognition by immune cells
    Jordan Kramer, P. Anton van der Merwe, Omer Dushek · 2025 · Immunology and Cell Biology
  23. A high-throughput two-cell assay for interrogating inhibitory signaling pathways in T cells
    Sumana Sharma, Toby Whitehead, Mateusz Kotowski, Emily Zhi Qing Ng, Joseph Clarke, Judith Maria Leitner, Yi‐Ling Chen, Ana Mafalda Santos, Peter Steinberger, Simon J. Davis · 2023 · Life Science Alliance
  24. The Search for Predictive Biomarkers in Response to Immune Checkpoint Inhibitors and Associated Adverse Events
    Marco Agostini, Pietro Traldi, Mahmoud H. Hamdan · 2025 · Journal of Personalized Medicine
  25. Beyond monoclonal antibodies: constraints and the case for alternative PD-1/PD-L1-targeting formats
    Natalia O Porozova, Natalia V. Petukhova, Maxim Gureev, Ivan Moiseev, Igor E. Eliseev, Liudmila V. Fedorova, Yuri B. Porozov · 2025 · Frontiers in Immunology
  26. SOHO State of the Art Updates and Next Questions | New Pathways and New Targets in PTCL: Staying on Target
    Shannon A. Carty, Carlos Murga‐Zamalloa, Ryan A. Wilcox · 2023 · Clinical Lymphoma Myeloma & Leukemia
  27. Using CombiCells, a platform enabling titration and combinatorial display of cell surface ligands, to study T cell antigen sensitivity by TCRs, CARs, and BiTEs
    Ashna Patel, Violaine André, Sofı́a Bustamante Eguiguren, Michael I. Barton, Jake Burton, Eleanor M Denham, Johannes Pettmann, Alexander M. Mørch, Mikhail A. Kutuzov, Jesús A. Siller‐Farfán et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  28. Ex vivo recapitulation of intramuscular mRNA vaccination with naïve and recall antigens using a human Lymphoid Follicle Chip platform
    Yunhao Zhai, Min‐Wen Ku, Ka Yang, Aditya Patil, Pranav Prabhala, Lirong He, Yuncheng Man, Sven B. Spörri, Supriya Gharpure, Abdul Rahman Isaacs et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  29. PD-1 suppresses CAR signaling by forming the inhibitory signalosome colocalizing to CAR microclusters
    Yosuke Yoshida, Hiroaki Machiyama, Ei Wakamatsu, Kensho Saito, Arata Takeuchi, Tetsushi Nishikawa, Ryohei Matsushima, Wataru Nishi, Hitoshi Nishijima, Yoshihiko Kanno et al. · 2026 · Communications Biology
  30. In vitro recapitulation of intramuscular mRNA vaccination with naive and recall antigens using a human lymphoid follicle chip platform
    Yunhao Zhai, Min‐Wen Ku, Ka Yang, Aditya Patil, Pranav Prabhala, Liqun He, Yuncheng Man, Mizanur Rahman, Kavya Menon, Sven B. Spörri et al. · 2026 · iScience
  31. OMICS – Mass Spectrometry-Based Proteomics in Systems Biology Research
    Peter Blattmann, Ruedi H. Aebersold · 2022 · Elsevier eBooks
  32. Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo , in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors
    Clémence Demerle, Laurent Gorvel, Marielle Mello, Sonia Pastor, Clara Degos, Ana Zarubica, Francesca Rigotti, Frédéric FIORE, Jacques A. Nunès, Bernard MALISSEN et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  33. HVEM/BTLA Immune Checkpoint Expression in Development of Gastric Cancer
    Maryam Azarafza, Mohsen Tehrani, Reza Valadan, Iradj Maleki, Seyed Mohammad Mehdi Ghaffari Hamedani, Alireza Ghanadan, Reza Alizadeh‐Navaei, Abolghasem Ajami · 2021 · Research Square
  34. Combined Therapy with Dendritic Cell Loaded-Exosomes Supplemented with PD-1 Inhibition Have Superior Antitumor Effect in Hepatocellular Carcinoma
    Shengbin Shi, Cuijuan Wang, Chuangnian Zhang, Wenyu Zhang, Yibo Qin, Zuoxing Niu · 2021 · Research Square
  35. A Genetic Variant of BTLA Gene is Related with Increased Risk and Clinical Manifestations of Breast Cancer in Chinese Women
    Ruipeng Zhao, Zhi Li, Chang Li, Kang Xu, Linlin Zhen, Wei Song, Jianhua Shi · 2020 · Research Square
  36. The Biology of Immune Checkpoint Blockade
    Timothy N. J. Bullock · 2024
  37. Evolutionary fingerprint in rodent PD1 confers weakened activity and enhanced tumor immunity compared to human PD1
    Takeya Masubuchi, Lin Chen, Nimi Marcel, George A. Wen, Christine Caron, Jibin Zhang, Zhao Yunlong, Gerald P. Morris, Xu Chen, Stephen Μ. Hedrick et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  38. The molecules with double-edged sword roles in T cell: An implication for adoptive T cell therapy
    Marziyeh Samiee, Saeedeh Salehi, Leila Mohamed Khosroshahi, Tahereh Soltantoyeh · 2025 · Critical Reviews in Oncology/Hematology
  39. miR-155-5p Silencing Does Not Alter BTLA Molecule Expression in CLL T Cells: Implications for Targeted Immunotherapy
    Agata Kosmaczewska, Lidia Ciszak, Anna Andrzejczak, Anna Tomkiewicz, Anna Partyka, Zofia Rojek-Gajda, Irena Frydecka, Dariusz Wołowiec, Tomasz Wróbel, Agnieszka A. Bojarska-Junak et al. · 2025 · Biomolecules
  40. Additional file 1 of Association of TRAIL receptor with phosphatase SHP-1 enables repressing T cell receptor signaling and T cell activation through inactivating Lck
    Chyuan, I-Tsu, Liao, Hsiu-Jung, Tan, Tse-Hua, Chuang, Huai-Chia, Chu, Yu-Chuan, Pan, Meng-Hsun, Wu, Chien-Sheng, Chu, Ching-Liang, Sheu, Bor-Ching, Hsu, Ping-Ning · 2024 · Figshare
  41. Additional file 3 of Association of TRAIL receptor with phosphatase SHP-1 enables repressing T cell receptor signaling and T cell activation through inactivating Lck
    Chyuan, I-Tsu, Liao, Hsiu-Jung, Tan, Tse-Hua, Chuang, Huai-Chia, Chu, Yu-Chuan, Pan, Meng-Hsun, Wu, Chien-Sheng, Chu, Ching-Liang, Sheu, Bor-Ching, Hsu, Ping-Ning · 2024 · Figshare
  42. Additional file 2 of Association of TRAIL receptor with phosphatase SHP-1 enables repressing T cell receptor signaling and T cell activation through inactivating Lck
    Chyuan, I-Tsu, Liao, Hsiu-Jung, Tan, Tse-Hua, Chuang, Huai-Chia, Chu, Yu-Chuan, Pan, Meng-Hsun, Wu, Chien-Sheng, Chu, Ching-Liang, Sheu, Bor-Ching, Hsu, Ping-Ning · 2024 · Figshare
  43. Tethered Signaling Proteins
    Jun F. Allard, Omer Dushek · 2026 · Annual Review of Biophysics
  44. THEMIS: new insights into its evolution, structure, and function
    Avik Dutta, Lakshminarayanan Aravind, S.J. Choi, Renaud Lesourne, Paul E. Love · 2026 · Trends in Immunology
  45. Quantitative interactomics of PD-1 and BTLA in primary T cells provides a rationale for concomitant coinhibitor blockade in cancer immunotherapy
    Yunhao Zhai · 2019
  46. Deciphering the role of the death receptor Fas/CD95 in T cell co-stimulation
    Giorgia Miloro · 2020
  47. Etude des syndromes lymphoprolifératifs lymphocytaires T induits par un dysfonctionnement de l'adaptateur moléculaire LAT
    Anaïs Joachim · 2021 · theses.fr (ABES)
  48. Dissection et caractérisation par analyse de spectrométrie de masse des assemblages moléculaires encodant la signalisation des lymphocytes T
    Kilian Ruminski · 2020
  49. Characterization of tumor-infiltrating myeloid cells in a mouse model of melanoma : roles of IL-4Rα signaling and tumor cell immunogenicity
    Elodie Baudoin · 2021 · theses.fr (ABES)
  50. Analyse protéomique et interactomique de l'activation des lymphocytes T humains primaires
    Philippe Nicolas · 2021
  51. Normal and pathological functions of the T cell signaling protein, THEMIS, in CD4+ T cells
    Cui Yang · 2021
  52. Comprendre et cibler la molécule intracellulaire "CISH" dans les cellules Natural Killer : une stratégie pour optimiser les traitements en immunothérapies
    Pierre-Louis Bernard · 2023 · theses.fr (ABES)
  53. Immune Checkpoint Inhibitors: Mechanisms and Emerging Challenges
    Gurpreet Singh Gill, Subhradip Karmakar, Sandeep Goswami · 2026 · Springer eBooks
  54. Enhanced mitochondrial fission promotes chemosensitivity via SHP-1 activity in triple-negative breast cancer
    Elizabeth K. Croom, Lillian E. Walton, Alessandro J. Bono, Anne Zhang, Brock A. Humphries · 2026 · Molecular Biology Reports
  55. Mutant HVEM in lymphoma disrupts BTLA and CD160 regulation of anti-tumor signaling
    Wai Lin, Sarah Huang, Mary Olivia Balmert, Ryan Bjordahl, Brian C. Ware, Aref Moshayedi, Jennifer Nguyen, Carl F. Ware, John R. Šedý · 2026 · Frontiers in Immunology